J&J’s Broad Device Portfolio Eclipses Lackluster Stent Sale Growth
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's medical device and diagnostics revenue grew 11.8% in the second quarter to $4.06 bil., despite a negligible increase in U.S. Cypher drug-eluting stent revenue from the year-ago period
You may also be interested in...
J&J Takes Cup-Half-Full Approach To Cypher’s 50% Share Of U.S. DES Market
Johnson & Johnson/Cordis is satisfied that Cypher retained 50% of the U.S. drug-eluting stent market in March as many clinicians tried Boston Scientific's Taxus
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.